ProblemRheumatology infusion teams lose days untangling prior auth, step therapy, biosimilar preferences, copay paperwork, and site-of-care rules before a first biologic can be scheduled. In one cohort, 71% of infusible meds required PA and initially denied cases stretched to a 50-day median.
SolutionRheumReady is the morning exception queue between prescription and schedulable infusion. It ingests referrals, payer rules, lab dates, and assistance forms, then tells staff which starts are ready, at risk, or blocked and drafts the exact next request back to the doctor, patient, or payer.
Market opportunityRheumatoid arthritis drugs alone are a $64.35B market in 2025, projected at $76.83B by 2035 by Precedence Research. Incumbents handle generic PA plumbing or broad infusion software, leaving a narrow $500-$1,500 per month clinic workflow wedge with fast payback.